"Antibodies, Neoplasm" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Immunoglobulins induced by antigens specific for tumors other than the normally occurring HISTOCOMPATIBILITY ANTIGENS.
| Descriptor ID |
D000912
|
| MeSH Number(s) |
D12.776.124.486.485.114.240 D12.776.124.790.651.114.240 D12.776.377.715.548.114.240
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Neoplasm".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Neoplasm".
This graph shows the total number of publications written about "Antibodies, Neoplasm" by people in this website by year, and whether "Antibodies, Neoplasm" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 0 | 2 | 2 |
| 2017 | 3 | 1 | 4 |
| 2018 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Antibodies, Neoplasm" by people in Profiles.
-
BRAF and MEK inhibitor therapy eliminates Nestin-expressing melanoma cells in human tumors. Pigment Cell Melanoma Res. 2018 11; 31(6):708-719.
-
Anti-SIRPa antibody immunotherapy enhances neutrophil and macrophage antitumor activity. Proc Natl Acad Sci U S A. 2017 12 05; 114(49):E10578-E10585.
-
Booming cancer immunotherapy fighting tumors. Sci China Life Sci. 2017 12; 60(12):1445-1449.
-
Comprehensive antibody profiles as personalized indicators of health and disease. Discov Med. 2017 10; 24(132):161-168.
-
What is the significance of onconeural antibodies for psychiatric symptomatology? A systematic review. BMC Psychiatry. 2017 05 03; 17(1):161.
-
Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood. 2009 Sep 24; 114(13):2589-97.
-
Development of BK nephropathy in recipients of simultaneous pancreas-kidney transplantation. Transplantation. 2009 Feb 27; 87(4):525-30.
-
Pharmacokinetics of alemtuzumab and the relevance in clinical practice. Leuk Lymphoma. 2008 Dec; 49(12):2256-62.
-
Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transplant. 2006 Oct; 6(10):2409-17.
-
Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer. 2003 Aug 15; 98(4):773-8.